AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32768001
Drug: ECCO2R therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ECCO2R therapy for ae‐COPD
Trial: 34967166
Drug: Longidaza 3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longidaza 3000 ME therapy in combination with tamsulosin
Trial: 34967166
Drug: Longidaza 3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longidaza 3000 ME therapy
Trial: 35092722
Drug: Everolimus (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (7.5 mg daily for first 3 days, 5.0 mg daily for days 4 and 5)
Trial: 33368026
Drug: Combination viloxazine
RxNorm normalized name: viloxazine
DrugBank: Viloxazine (DB09185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination viloxazine ER (700 mg) + methylphenidate (36 mg)
Trial: 33368026
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER (700 mg) alone
Trial: 33368026
Drug: Methylphenidate (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (36 mg) alone
Trial: 32027763
Drug: Adapted evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted evidence-based intervention from U.S. for disruptive behavior disorders (DBDs) in Uganda, details on dosage and duration not available.
Trial: 32665034
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.6 μg/kg for 10 min after central vein catheterization, followed by 0.4 μg/kg/h until the end of surgery)
Trial: 35906554
Drug: Opioid-free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free anesthesia with dexmedetomidine (loading dose 0.6 μg·kg−1 for 10 min, then 0.5 μg·kg−1·h−1 continuous infusion) and sevoflurane plus bilateral paravertebral blockade (0.2 μg·kg−1 dexmedetomidine and 0.5% ropivacaine 15 ml per side)
Trial: 35906554
Drug: Opioid-based anesthesia
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-based anesthesia with remifentanil, sevoflurane, and bilateral paravertebral blockade (0.5% ropivacaine 15 ml per side)
Trial: 34910136
Drug: Anacetrapib 100
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 100 mg daily
Trial: 32645771
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide (NO) administration during cardiopulmonary bypass (CPB)
Trial: 32645771
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration during cardiopulmonary bypass (CPB)
Trial: 34083615
Drug: Anfibatide administered
RxNorm normalized name: Anfibatide
DrugBank: Anfibatide (DB15094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anfibatide administered intravenously as a single dose bolus or a bolus followed by a constant rate infusion for 24 hours
Trial: 34920734
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg once-daily
Trial: 34920734
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg once-daily
Trial: 36131360
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg alone
Trial: 36131360
Drug: SHR4640 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 10 mg alone
Trial: 33992100
Drug: Local exercise
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local exercise therapy
Trial: 32321172
Drug: L‐asparaginase (L‐ASP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐asparaginase (L‐ASP) therapy
Trial: 32321172
Drug: L‐ASP reintroduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐ASP reintroduction
Trial: 35287591
Drug: sintilimab immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab immunotherapy combined with XELOX chemotherapy
Trial: 33559248
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of Donor Health Questionnaire (DHQ) and antibody testing
Trial: 32922193
Drug: Ephedrine 20
RxNorm normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 20 mg intramuscularly
Trial: 36026840
Drug: Nifedipine gastrointestinal
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine gastrointestinal therapeutic system (GITS) 30 mg once daily
Trial: 33514760
Drug: RRR‐α‐tocopherol (ALC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR‐α‐tocopherol (ALC) at doses of 50, 75, 100, and 150 mg/kg of diet
Trial: 33514760
Drug: No added
RxNorm normalized name: Soy-based no added carbohydrate infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No added α‐tocopherol in the feed (0 dose)
Trial: 34954095
Drug: Hydroxychloroquine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (daily HCQ)
Trial: 34954095
Drug: Hydroxychloroquine (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (weekly HCQ)
Trial: 32493624
Drug: Polymer bur
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer bur with 75% ethanol pre-treatment
Trial: 36219925
Drug: Respiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory muscle training (RMT) with a threshold resistance device, daily, twice a day for three sets of 15 repetitions for 8 weeks
Trial: 616062859
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MKS and p21
Trial: 32075406
Drug: Eptinezumab 30
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab 30 mg
Trial: 33528063
Drug: First-line treatments
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatments (various types including chemotherapy and radiotherapy)
Trial: 33528063
Drug: Chemotherapy (CH)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CH) and radiotherapy (RT)
Trial: 33528063
Drug: Chemotherapy (CH)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CH) only
Trial: 35226083
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel plus bevacizumab
Trial: 35226083
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel plus placebo
Trial: 35226083
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel (group C)
Trial: 35610625
Drug: Elian Granules
RxNorm normalized name: Lian Fang
DrugBank: Nelumbo nucifera flower (DB14333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elian Granules (24.2 g, two small bags, twice a day for 24 weeks)
Trial: 35610625
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two small bags, twice a day for 24 weeks)
Trial: 32557000
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (fractional 2940-nm Er:YAG laser + 5% amorolfine lacquer)
Trial: 32557000
Drug: Monotherapy (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (5% amorolfine lacquer)
Trial: 39002945
Drug: Rivaroxaban with
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban with aspirin
Trial: 35266202
Drug: Pneumatic jet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic jet injection (PJI) with 5-fluorouracil (5-FU) and triamcinolone acetonide (TAC)
Trial: 33499847
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg ART (ig) treatment diabetic
Trial: 33499847
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg ART (ig) treatment diabetic
Trial: 33499847
Drug: 6 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 U/kg insulin (iH) treatment diabetic
Trial: 33761461
Drug: Moderate-load (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-load (ML) half-squat priming (65% 1RM)
Trial: 32567238
Drug: YiqiFumai lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YiqiFumai lyophilized injection (5.2 g/day)
Trial: 33219590
Drug: Dry topical
RxNorm normalized name: Savlon Dry Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry topical heat for 7 min using two hot seed bags (N=21)
Trial: 33219590
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of heat and pressure (N=20)
Trial: 32221332
Drug: Sodium picosulfate/magnesium
RxNorm normalized name: CITRIC ACID/SODIUM PICOSULFATE/MAGNESIUM OXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium picosulfate/magnesium citrate (PSMC) preparation-Bowklean
Trial: 35768736
Drug: Intravenous clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clindamycin
Trial: 34405393
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) plus oral arsenic (realgar-indigo naturalis formula)
Trial: 34405393
Drug: PML-RARA transcript
RxNorm normalized name: nogapendekin alfa inbakicept-pmln Injection [Anktiva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PML-RARA transcript level of ≥6.5% at the end of induction therapy
Trial: 33020898
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone 100 mg
Trial: 33020898
Drug: Oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral progesterone 400 mg
Trial: 33020898
Drug: Matching transdermal/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching transdermal/oral placebo
Trial: 36052175
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training (ST) high volume (3 sets per exercise) + photobiomodulation therapy (PBMt)
Trial: 36052175
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training (ST) low volume (1 set per exercise) + photobiomodulation therapy (PBMt)
Trial: 34169551
Drug: Adjunct use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct use of deproteinized bovine bone mineral (DBBM) and native bilayer collagen membrane (NBCM)
Trial: 35987208
Drug: Point-of-care viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care viral load testing every 3 months, targeted drug resistance mutation testing, and clinical decision support.
Trial: 35987208
Drug: Targeted drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted drug resistance mutation testing in intervention participants.
Trial: 33986070
Drug: Short duration
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short duration treatment strategy (antibiotics may be stopped as early as day 3 if respiratory cultures are negative, and day 5 if positive)
Trial: 33986070
Drug: Standard-of-care duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care duration arm (antibiotics for at least 8 days)
Trial: 33986070
Drug: Short duration
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short duration treatment strategy
Trial: 35587457
Drug: Weekly intramuscular
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intramuscular (IM) 17 hydroxyprogesterone (17‐OHP)
Trial: 36111381
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of DIM (300 mg of DIM-BR®) daily for 30 days
Trial: 35431172
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg monthly for 52 weeks
Trial: 34544808
Drug: 6-month salsa
RxNorm normalized name: CISTANCHE SALSA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month salsa dance training intervention, 2 weekly 1-hour sessions
Trial: 32186977
Drug: Beef protein
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef protein supplementation (BEEF), 25 g daily for 8 weeks
Trial: 32186977
Drug: Isoenergetic carbohydrates
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic carbohydrates (CHO) supplement
Trial: 33211769
Drug: Cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping therapy with negative pressure of 400 mmHg for 15 minutes, twice a week, for 4 weeks
Trial: 34176448
Drug: Extended-Release Injectable
RxNorm normalized name: Exenatide for Extended-Release Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release Injectable Naltrexone (XR-NTX)
Trial: 34854982
Drug: Intradialytic cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic cycling (IDC), 30 min of moderate intensity (RPE 12-14), thrice weekly for 6 months
Trial: 36241492
Drug: Malkia Klabu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malkia Klabu intervention (girl-friendly drug shops)
Trial: 35768875
Drug: Interactive text
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive text messaging intervention (iTAB-CV) with daily texts for 2 months, followed by either high or low booster texts for an additional 2 months
Trial: 35768875
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of medication taking, mood, and home blood pressure
Trial: 35672892
Drug: Yinhua Miyanling
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Yinhua Miyanling tablets (YMT) 2 g qid orally
Trial: 35672892
Drug: Placebo (dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dummy YMT) 2 g qid orally
Trial: 32993256
Drug: Butorphanol patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol patient‐controlled intravenous analgesia (0.15 mg/kg)
Trial: 32993256
Drug: Sufentanil patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil patient‐controlled intravenous analgesia (1.5 μg/kg)
Trial: 32993256
Drug: Butorphanol patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol patient‐controlled intravenous analgesia
Trial: 35466481
Drug: Lamisil AT
RxNorm normalized name: LamISIL AT
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamisil AT 1% spray
Trial: 33094868
Drug: Systemic family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic family treatment
Trial: 34780095
Drug: NAL‐ER162 (162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAL‐ER162 (162 mg twice daily)
Trial: 34780095
Drug: NAL‐ER81 (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAL‐ER81 (81 mg twice daily)
Trial: 32933995
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitor (PPI) use
Trial: 35412366
Drug: Leptomeningeal metastatic
RxNorm normalized name: Kiss-1 metastasis suppressor
DrugBank: Kisspeptin (DB19112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptomeningeal metastatic dissemination before treatment
Trial: 32891738
Drug: D-index-guided early
RxNorm normalized name: MAGNI-GUIDE (B-D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-index-guided early antifungal therapy (DET) using micafungin
Trial: 32891738
Drug: Empirical antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antifungal therapy (EAT) using micafungin
Trial: 35857327
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message intervention stating a vaccine had been reserved, with scheduled vaccination date and follow-up reminders.
Trial: 34563211
Drug: Anakinra (Kineret®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (Kineret®), a human recombinant interleukin‐1 receptor antagonist (rhIL1ra)
Trial: 34294072
Drug: Zinc chloride
RxNorm normalized name: Zinc Chloride
DrugBank: Zinc chloride (DB14533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc chloride mouthwash (7.5 ml, rinsed every 8 hours for 2 minutes)
Trial: 32951067
Drug: 12.5 g
RxNorm normalized name: glycerin 12.5 GM per 20.4 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 g Litesse®Ultra (PDX)
Trial: 36215323
Drug: Monthly sulfadoxine/pyrimethamine‐amodiaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulfadoxine/pyrimethamine‐amodiaquine (SP‐AQ)
Trial: 34121333
Drug: Lower-sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-sodium oxybate (LXB) 4.5 g
Trial: 34121333
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) 4.5 g
Trial: 35550405
Drug: Standard arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm (standard radiation therapy plan without 3He MRI)
Trial: 35302931
Drug: Daily Model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Model (DM)
Trial: 35302931
Drug: Weekly Model
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly Model (WM)
Trial: 32398047
Drug: Canrenone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenone (200 mg intravenously within 2-3 min)
Trial: 33147327
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 g single dose
Trial: 35483886
Drug: OB (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OB (40 mg three times a day)
Trial: 34973304
Drug: 0.5% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine, 30 mL to 14 mL
Trial: 34973304
Drug: 0.5% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine, 14 mL
Trial: 34973304
Drug: 0.5% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine, 30 mL
Trial: 34973304
Drug: 0.5% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine, 12 mL
Trial: 35759124
Drug: PDS 10
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PDS 10 mg/ml
Trial: 35759124
Drug: PDS 40
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PDS 40 mg/ml
Trial: 35759124
Drug: PDS 100
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PDS 100 mg/ml
Trial: 35427803
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab 0.5 mg
Trial: 36321459
Drug: Sacubitril/valsartan (97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (97/103 mg twice daily)
Trial: 34526064
Drug: Ketamine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusions (six total)
Trial: 34526064
Drug: Ketamine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusions (six total) in pain group
Trial: 34526064
Drug: Ketamine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusions (six total) in non-pain group
Trial: 33565042
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available treatment (BAT)
Trial: 33167920
Drug: TS-141 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-141 30 mg once a day
Trial: 33167920
Drug: TS-141 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-141 60 mg once a day
Trial: 33167920
Drug: TS-141 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-141 120 mg (60 mg twice a day)
Trial: 35552788
Drug: 8-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-day antibiotic treatment
Trial: 35552788
Drug: 15-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-day antibiotic treatment
Trial: 34270458
Drug: COVID-19 vaccines
RxNorm normalized name: Covid-19 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccines (specific vaccines and dosages not mentioned)
Trial: 35079115
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg twice daily for 8 weeks, followed by bicalutamide 50 mg/day
Trial: 35079115
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg/day alone (after 8 weeks of observation)